Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration

Du Feng; Huixin Jiang; Gengjia Chen; Wenhui Guan; Lin Yi; Yue Zhu; Yijia Li; Gengda Huang; Bin He; Junlong Tang; Yujie Tang; Jiyuan Zeng; Wensheng Zhou; Jiayu Shi; Zhanhong Xie; Ming Liu; Xiaohong Xie; Xinqing Lin; Chengzhi Zhou

doi:10.3389/fimmu.2024.1485358

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration

Front Immunol. 2024 Dec 9:15:1485358. doi: 10.3389/fimmu.2024.1485358. eCollection 2024.

Authors

Du Feng^#^{1

2}, Huixin Jiang^#¹, Gengjia Chen^#^{1

2}, Wenhui Guan¹, Lin Yi², Yue Zhu¹, Yijia Li¹, Gengda Huang¹, Bin He¹, Junlong Tang³, Yujie Tang¹, Jiyuan Zeng¹, Wensheng Zhou¹, Jiayu Shi⁴, Zhanhong Xie¹, Ming Liu¹, Xiaohong Xie¹, Xinqing Lin¹, Chengzhi Zhou¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
² Nanshan School, Guangzhou Medical University, Guangzhou, Guangdong, China.
³ The First School of Clinical Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China.
⁴ Department of Stomatology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

^# Contributed equally.

Abstract

The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for front-line treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS). This case highlights the potential efficacy and feasibility of combining immunotherapy with chemotherapy in patients with STK11-mutant NSCLC. Additionally, we provide a review of recent advancements in research related to STK11 mutations in lung cancer as reported in the literature.

Keywords: STK11 mutation; cadonilimab; case report; front-line therapy; lung adenocarcinoma.

Publication types

Case Reports

MeSH terms

AMP-Activated Protein Kinase Kinases*
Adenocarcinoma of Lung* / drug therapy
Adenocarcinoma of Lung* / genetics
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Carboplatin / administration & dosage
Carboplatin / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics
Female
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Male
Middle Aged
Mutation*
Pemetrexed / administration & dosage
Pemetrexed / therapeutic use
Protein Serine-Threonine Kinases / genetics
Treatment Outcome

Substances

STK11 protein, human
AMP-Activated Protein Kinase Kinases
Antibodies, Monoclonal, Humanized
Carboplatin
Pemetrexed
Protein Serine-Threonine Kinases

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by National Key R&D Program of China (2021YFC2301101) and Guangzhou Science and Technology Major Clinical Project (2023C-DZ06).